Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025

Core Viewpoint - Vivoryon Therapeutics N.V. has announced its 2025 Annual General Meeting scheduled for June 24, 2025, focusing on its clinical stage biotechnology initiatives aimed at developing small molecule medicines for various severe diseases [1]. Company Overview - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company dedicated to the discovery and development of innovative small molecule-based medicines [2]. - The company aims to improve the lives of patients suffering from severe diseases by leveraging its expertise in post-translational modifications to develop medicines that modulate the activity and stability of pathologically altered proteins [2]. - Vivoryon has established a pipeline of orally available small molecule inhibitors targeting conditions such as Alzheimer's disease, inflammatory and fibrotic disorders, including kidney issues, and cancer [2].